Children and SARS-CoV-2

Dusan Bogunovic; Miriam Merad

doi:10.1016/j.chom.2021.06.015

Children and SARS-CoV-2

Cell Host Microbe. 2021 Jul 14;29(7):1040-1042. doi: 10.1016/j.chom.2021.06.015.

Authors

Dusan Bogunovic¹, Miriam Merad²

Affiliations

¹ Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center of Inborn Errors of Immunity, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological science, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: dusan.bogunovic@mssm.edu.
² Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological science, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: miram.merad@mssm.edu.

Abstract

A previously immune-naive world population is experiencing natural infection with SARS-CoV-2. Severe COVID-19 predominantly impacts adults, yet multisystem inflammatory disorder primarily impacts children. Herein, we discuss known clinical and biological features of SARS-CoV-2 in children and reflect on currently identified immune features and discuss what remains unknown.

MeSH terms

COVID-19 / immunology*
COVID-19 / physiopathology*
Child
Hospitalization
Humans
Immunity
SARS-CoV-2
Vaccination